We are monitoring the impact of COVID-19 on APAC Preclinical In-vivo Imaging Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 535
Share on
Share on

Asia Pacific Preclinical In-vivo Imaging Market Research Report – Segmented By Modality, Reagent & By Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 535
Pages: 135

APAC Preclinical In-Vivo Imaging Market Size & Growth (2021 to 2026)

The Preclinical in-vivo imaging market in the Asia Pacific has been estimated at USD 159.59 Million in 2021. It is projected to reach USD 245.54 Million by 2026, at a CAGR of 9.00% during the forecast period.

The market for preclinical In-vivo imaging in the APAC region is primarily driven by the increasing burden of cardiovascular diseases, cancer, and other diseases. Also, the growing demand for effective diagnosis and real-time monitoring treatment efficiency is expected to boost the market growth.  In addition, the ever-increasing population with the rise in the ever-increasing elderly population is significantly influencing the In-vivo imaging market. The senior population is more prone to various chronic diseases such as cancer, cardiovascular, and other conditions driving the market growth. 

On the other hand, the increasing initiatives and investments by the government for infrastructure development, research and development activities, and medical tourism for creating awareness among the people are expected to encourage market growth. In addition, other factors such as raising awareness about the imaging and screening tests available in the market, increasing demand for non-invasive imaging and diagnosing purposes are accelerating the preclinical in-vivo imaging market growth during the forecast period. 

Furthermore, the rise in technological advancements in the preclinical in-vivo imaging market for developing better molecular imaging modalities and methods for testing samples, as well as the rise in growing acceptance for development tools of preclinical imaging as a legitimate drug, are most likely to provide lucrative growth opportunities to the market preclinical in-vivo imaging market growth in this region. Moreover, the key market players are implementing various market strategies to gain a competitive advantage over the marketplace. The strategies include installations, acquisitions, and mergers. 

However, the high cost of equipment, rising installation, and operational costs for preclinical imaging systems hamper the APAC preclinical in-vivo imaging market growth. On the other hand, the approval procedure for preclinical imaging equipment is lengthy and time-consuming, and strict government restrictions make product entrance more challenging. As a result, fewer companies enter the market, limiting APAC market development in preclinical in-vivo imaging.

This research report on the Asia Pacific preclinical in-vivo imaging market has been segmented and sub-segmented into the following categories:

By Modality:

  • optical Imaging
  • Nuclear Imaging
  • Micro-MRI
  • Micro-CT
  • Micro-ultrasound
  • Photoacoustic
  • Magnetic Particle Imaging Systems

By Reagent:

  • optical Imaging Reagents
  • Nuclear Imaging Reagents
  • MRI Contrast Agents
  • Ultrasound Contrast Agents
  • CT Contrast Agents

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the Asia Pacific is one of the fastest-growing regions globally in the preclinical in-vivo imaging market. However, it is estimated to show significant market share during the forecast period. The regional market growth is projected to be fuelled by the Improving healthcare sectors, increasing population with the rise in the geriatric population, and favorable reimbursement. In addition, emerging countries such as China, Japan, and India are significantly contributing to the APAC regional market growth.

China is predicted to dominate the APAC Preclinical in-vivo imaging market over the forecast period, and it is anticipated to account for the predominant share during the forecast period. This is because China has witnessed technological advancements in the healthcare sector. Also, the growing geriatric population and increasing prevalence of chronic diseases are propelling the market growth in the country. In addition, growing awareness and adoption of non-invasive imaging tests as the test or this non-invasive approach consist lower risk of infections compared to traditional ones with less recovery time is expected to fuel the market growth.

India is one of the fastest-growing countries in the Asia Pacific. India is anticipated to witness a promising in the preclinical In-vivo imaging market in the coming years. Increasing chronic disorders, improving healthcare sectors, and supportive government policies are expected to expand the market growth.

KEY MARKET PLAYERS:

A few notable players in the APAC Preclinical in-vivo imaging market profiled in this report are Aspect Imaging, Biospace Lab S.A., Bruker Corporation, LI-COR Biosciences, Mediso Ltd., MILabs B.V., MR Solutions Ltd, PerkinElmer, Inc., TriFoil Imaging, and FUJIFILM VisualSonics, Inc.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Modality                

                                5.1.1 Optical imaging      

                                                5.1.1.1 Bioluminescence/fluorescence imaging systems

                                                5.1.1.2 Standalone fluorescence imaging systems

                                                5.1.1.3 Optical + X-ray/optical + CT imaging systems

                                5.1.2 Nuclear imaging    

                                                5.1.2.1 Micro-PET systems (standalone PET, PET/CT, and PET/MRI)

                                                5.1.2.2 Micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI)

                                                5.1.2.3 Tri-modality (PET/SPECT/CT) imaging systems

                                5.1.3 Micro-MRI               

                                5.1.4 Micro-CT  

                                5.1.5 Micro-ultrasound 

                                5.1.6 Photoacoustic        

                                5.1.7 Magnetic particle imaging systems               

                5.2 By Reagent                 

                                5.2.1 Optical imaging reagents   

                                                5.2.1.1 Bioluminescent reagents

                                                5.2.1.2 Fluorescent imaging reagents

                                5.2.2 Nuclear imaging reagents 

                                                5.2.2.1 Preclinical PET tracers

                                                5.2.2.2 Preclinical SPECT probes

                                5.2.3 MRI contrast agents            

                                5.2.4 Ultrasound contrast agents             

                                5.2.5 CT contrast agents               

6. Geographical Analysis                                              

                6.3 Asia-Pacific                 

                                6.1 Introduction               

                                6.2 China             

                                6.3 India              

                                6.4 Japan            

                                6.5 South Korea               

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Aspect Imaging                         

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Strategic Evaluation and Operations            

                                8.1.4 Financial analysis  

                                8.1.5 Legal issues             

                                8.1.6 Recent Developments       

                                8.1.7 SWOT analysis       

                                8.1.8 Analyst View          

                8.2 Biospace Lab S.A.                     

                8.3 Bruker Corporation                 

                8.4 LI-COR Biosciences                  

                8.5 Mediso Ltd.                

                8.6 MILabs B.V.                

                8.7 MR Solutions Ltd                      

                8.8 PerkinElmer               

                8.9 TriFoil Imaging                           

                8.10 FUJIFILM VisualSonics, Inc.                                

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Expert Opinions                                        

                10.1 Market Outlook                     

                10.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Preclinical in-vivo imaging Market By Region, From 2021 to 2026 (USD Million)
  2. Asia-Pacific Preclinical in-vivo imaging Market By Modality, From 2021 to 2026 (USD Million)
  3. Asia-Pacific Preclinical Optical imaging Market By Region, From 2021 to 2026 (USD Million)
  4. Asia-Pacific Preclinical Bioluminescence/fluorescence imaging systems Market By Region, From 2021 to 2026 (USD Million)
  5. Asia-Pacific Preclinical Standalone fluorescence imaging systems Market By Region, From 2021 to 2026 (USD Million)
  6. Asia-Pacific Preclinical Optical + X-ray/optical + CT imaging systems Market By Region, From 2021 to 2026 (USD Million)
  7. Asia-Pacific Preclinical Nuclear imaging Market By Region, From 2021 to 2026 (USD Million)
  8. Asia-Pacific Preclinical Micro-PET systems (standalone PET, PET/CT, and PET/MRI) Market By Region, From 2021 to 2026 (USD Million)
  9. Asia-Pacific Preclinical Micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI) Market By Region, From 2021 to 2026 (USD Million)
  10. Asia-Pacific Preclinical Tri-modality (PET/SPECT/CT) imaging systems Market By Region, From 2021 to 2026 (USD Million)
  11. Asia-Pacific Preclinical Micro-MRI Market By Region, From 2021 to 2026 (USD Million)
  12. Asia-Pacific Preclinical Micro-CT Market By Region, From 2021 to 2026 (USD Million)
  13. Asia-Pacific Preclinical Micro-ultrasound Market By Region, From 2021 to 2026 (USD Million)
  14. Asia-Pacific Preclinical Photoacoustic Market By Region, From 2021 to 2026 (USD Million)
  15. Asia-Pacific Preclinical Magnetic particle imaging systems Market By Region, From 2021 to 2026 (USD Million)
  16. Asia-Pacific Preclinical in-vivo imaging Market By Reagent, From 2021 to 2026 (USD Million)
  17. Asia-Pacific Preclinical Optical imaging reagents Market By Region, From 2021 to 2026 (USD Million)
  18. Asia-Pacific Preclinical Bioluminescent reagents Market By Region, From 2021 to 2026 (USD Million)
  19. Asia-Pacific Preclinical Fluorescent imaging reagents Market By Region, From 2021 to 2026 (USD Million)
  20. Asia-Pacific Preclinical Nuclear imaging reagents Market By Region, From 2021 to 2026 (USD Million)
  21. Asia-Pacific Preclinical PET tracers Market By Region, From 2021 to 2026 (USD Million)
  22. Asia-Pacific Preclinical SPECT probes Market By Region, From 2021 to 2026 (USD Million)
  23. Asia-Pacific Preclinical MRI contrast agents Market By Region, From 2021 to 2026 (USD Million)
  24. Asia-Pacific Preclinical Ultrasound contrast agents Market By Region, From 2021 to 2026 (USD Million)
  25. Asia-Pacific Preclinical CT contrast agents Market By Region, From 2021 to 2026 (USD Million)
  26. China Preclinical in-vivo imaging Market By Modality, From 2021 to 2026 (USD Million)
  27. China Preclinical Optical Imaging Market By Optical imaging, From 2021 to 2026 (USD Million)
  28. China Preclinical Nuclear Imaging Market By Preclinical Nuclear imaging, From 2021 to 2026 (USD Million)
  29. China Preclinical in-vivo imaging Market By Reagent, From 2021 to 2026 (USD Million)
  30. China Preclinical Optical imaging reagents Market By Optical imaging reagents, From 2021 to 2026 (USD Million)
  31. China Preclinical Nuclear imaging reagents Market By Nuclear imaging reagents, From 2021 to 2026 (USD Million)
  32. India Preclinical in-vivo imaging Market By Modality, From 2021 to 2026 (USD Million)
  33. India Preclinical Optical Imaging Market By Optical imaging, From 2021 to 2026 (USD Million)
  34. India Preclinical Nuclear Imaging Market By Preclinical Nuclear imaging, From 2021 to 2026 (USD Million)
  35. India Preclinical in-vivo imaging Market By Reagent, From 2021 to 2026 (USD Million)
  36. India Preclinical Optical imaging reagents Market By Optical imaging reagents, From 2021 to 2026 (USD Million)
  37. India Preclinical Nuclear imaging reagents Market By Nuclear imaging reagents, From 2021 to 2026 (USD Million)
  38. Japan Preclinical in-vivo imaging Market By Modality, From 2021 to 2026 (USD Million)
  39. Japan Preclinical Optical Imaging Market By Optical imaging, From 2021 to 2026 (USD Million)
  40. Japan Preclinical Nuclear Imaging Market By Preclinical Nuclear imaging, From 2021 to 2026 (USD Million)
  41. Japan Preclinical in-vivo imaging Market By Reagent, From 2021 to 2026 (USD Million)
  42. Japan Preclinical Optical imaging reagents Market By Optical imaging reagents, From 2021 to 2026 (USD Million)
  43. Japan Preclinical Nuclear imaging reagents Market By Nuclear imaging reagents, From 2021 to 2026 (USD Million)
  44. South Korea Preclinical in-vivo imaging Market By Modality, From 2021 to 2026 (USD Million)
  45. South Korea Preclinical Optical Imaging Market By Optical imaging, From 2021 to 2026 (USD Million)
  46. South Korea Preclinical Nuclear Imaging Market By Preclinical Nuclear imaging, From 2021 to 2026 (USD Million)
  47. South Korea Preclinical in-vivo imaging Market By Reagent, From 2021 to 2026 (USD Million)
  48. South Korea Preclinical Optical imaging reagents Market By Optical imaging reagents, From 2021 to 2026 (USD Million)
  49. South Korea Preclinical Nuclear imaging reagents Market By Nuclear imaging reagents, From 2021 to 2026 (USD Million)
  50. Australia Preclinical in-vivo imaging Market By Modality, From 2021 to 2026 (USD Million)
  51. Australia Preclinical Optical Imaging Market By Optical imaging, From 2021 to 2026 (USD Million)
  52. Australia Preclinical Nuclear Imaging Market By Preclinical Nuclear imaging, From 2021 to 2026 (USD Million)
  53. Australia Preclinical in-vivo imaging Market By Reagent, From 2021 to 2026 (USD Million)
  54. Australia Preclinical Optical imaging reagents Market By Optical imaging reagents, From 2021 to 2026 (USD Million)
  55. Australia Preclinical Nuclear imaging reagents Market By Nuclear imaging reagents, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample